期刊
JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY
卷 41, 期 1, 页码 56-63出版社
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/MPH.0000000000001257
关键词
pediatric; decision making; decision aids; treatment preference; hydroxyurea
资金
- Agency for Healthcare Research and Quality's (AHRQ) Centers for Education and Research in Therapeutics (CERTs) [1U19HS021114]
- Health Resources and Services Administration (HRSA) Sickle Cell Disease Treatment Demonstration Program [U1EMC27863]
- Health Resources and Services Administration (HRSA) Sickle Cell Disease Treatment Demonstration Program Sickle Cell Disease Treatment Demonstration Program [HHSH25020100022C]
National evidence-based guidelines recommend offering hydroxyurea to patients with sickle cell anemia 9 months of age and older using shared decision making, but offer no strategies to aid implementation. We developed a hydroxyurea multicomponent decision aid via a needs assessment, clinic observations, and iterative feedback to address parent decision needs and promote a discussion between clinicians and parents. A total of 75 parents and 28 clinicians participated across all phases. The decision aid was rated as useful. Hydroxyurea knowledge improved and decisional conflict decreased supporting the potential for use to facilitate shared decision making in pediatric sickle cell anemia.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据